JPH0455173B2 - - Google Patents

Info

Publication number
JPH0455173B2
JPH0455173B2 JP58500925A JP50092583A JPH0455173B2 JP H0455173 B2 JPH0455173 B2 JP H0455173B2 JP 58500925 A JP58500925 A JP 58500925A JP 50092583 A JP50092583 A JP 50092583A JP H0455173 B2 JPH0455173 B2 JP H0455173B2
Authority
JP
Japan
Prior art keywords
methylamine
amine
cytotoxic
immunotoxin
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58500925A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59500371A (ja
Inventor
Furantsu Jensen
Pieeru Gurosu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JPS59500371A publication Critical patent/JPS59500371A/ja
Publication of JPH0455173B2 publication Critical patent/JPH0455173B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP58500925A 1982-03-11 1983-03-07 免疫毒素とアミンとを含む細胞毒性薬剤 Granted JPS59500371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8204119A FR2536997B1 (fr) 1982-03-11 1982-03-11 Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
FR82/04119 1982-03-11

Publications (2)

Publication Number Publication Date
JPS59500371A JPS59500371A (ja) 1984-03-08
JPH0455173B2 true JPH0455173B2 (https=) 1992-09-02

Family

ID=9271880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58500925A Granted JPS59500371A (ja) 1982-03-11 1983-03-07 免疫毒素とアミンとを含む細胞毒性薬剤

Country Status (7)

Country Link
US (1) US4614650A (https=)
EP (1) EP0089270B1 (https=)
JP (1) JPS59500371A (https=)
AT (1) ATE28566T1 (https=)
DE (1) DE3372708D1 (https=)
FR (1) FR2536997B1 (https=)
WO (1) WO1983003200A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
JP2006100141A (ja) * 2004-09-29 2006-04-13 Toshiba Corp 付臭剤、燃料電池用液体燃料及び燃料電池
GB0507672D0 (en) * 2005-04-15 2005-05-25 Barnaba Vincenzo Adjuvant
JP4444355B2 (ja) * 2008-09-03 2010-03-31 株式会社東芝 燃料電池

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine
JPS57197223A (en) * 1981-05-27 1982-12-03 Eisai Co Ltd Immunoenhancing agent containing ricin b chain
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer

Also Published As

Publication number Publication date
FR2536997A1 (fr) 1984-06-08
DE3372708D1 (en) 1987-09-03
WO1983003200A1 (fr) 1983-09-29
EP0089270A1 (fr) 1983-09-21
ATE28566T1 (de) 1987-08-15
EP0089270B1 (fr) 1987-07-29
JPS59500371A (ja) 1984-03-08
FR2536997B1 (fr) 1987-08-07
US4614650A (en) 1986-09-30

Similar Documents

Publication Publication Date Title
JP2025066807A (ja) 生体直交型組成物
JP2020510671A5 (https=)
JPH01146829A (ja) 超音波による腫瘍治療用生理作用増強剤
GB2271059A (en) Pharmaceutical compositions comprising aconitane derivatives
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
CN114829447A (zh) 刷前药及其用途
JP2020523354A5 (https=)
CN106999540A (zh) 组合疗法
TWI612965B (zh) 玻尿酸之用途及疼痛抑制用醫藥組成物
JPH0455173B2 (https=)
JP2024036660A (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
JP2006508977A5 (https=)
KR940702726A (ko) 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법
Rubens Antibodies as carriers of anticancer agents
JPH0455172B2 (https=)
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
US5547956A (en) Pharmaceutical composition and the method for treating drug addicts' withdrawal syndromes and detoxifying addicts by the same
JPH04500670A (ja) ウイルス感染の治療用方法及び組成物
Obrist et al. Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates
KR930702985A (ko) 식도암의 치료
KR930702984A (ko) 비-소세포 폐암의 치료
JPS59500272A (ja) 抗ガン剤
KR910016331A (ko) 허혈성 질환 치료제
KR930702983A (ko) 난소암의 치료
Paris et al. Lack of Neurotoxicity After Intra-Raphe Micro-Injections of MDMA (“Ecstasy”)